Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 DiabetesManuela Battaglia, Mark Peakman, Linda A. DiMeglio et al.|Diabetes Care|2019Cited by 350
Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 DiabetesMichael J. Haller, W. J. Russell, Desmond Schatz et al.|Diabetes Care|2018Cited by 183
Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetesMichael J. Haller, Desmond Schatz, Stephen E. Gitelman et al.|Journal of Clinical Investigation|2014Cited by 164
Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial DataMichael J. Haller, Louis H. Philipson, S. Alice Long et al.|Diabetes|2019Cited by 132